A detailed history of Nuveen Asset Management, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 380,535 shares of AKBA stock, worth $799,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares
380,535
Previous 380,535 -0.0%
Holding current value
$799,123
Previous $388,000 29.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.86 - $1.63 $327,260 - $620,272
380,535 New
380,535 $388,000
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $417,676 - $1.7 Million
-580,106 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $16,061 - $23,737
7,107 Added 1.24%
580,106 $1.33 Million
Q3 2021

Nov 12, 2021

SELL
$2.35 - $3.88 $16,475 - $27,202
-7,011 Reduced 1.21%
572,999 $1.66 Million
Q2 2021

Aug 16, 2021

BUY
$2.83 - $4.2 $179,045 - $265,721
63,267 Added 12.24%
580,010 $2.2 Million
Q1 2021

May 17, 2021

SELL
$2.92 - $5.06 $876 - $1,517
-300 Reduced 0.06%
516,743 $1.75 Million
Q4 2020

Feb 16, 2021

SELL
$2.22 - $3.78 $2.56 Million - $4.37 Million
-1,154,823 Reduced 69.07%
517,043 $5.17 Million
Q3 2020

Nov 16, 2020

BUY
$2.39 - $13.08 $236,433 - $1.29 Million
98,926 Added 6.29%
1,671,866 $16.7 Million
Q2 2020

Aug 14, 2020

BUY
$6.67 - $13.58 $580,850 - $1.18 Million
87,084 Added 5.86%
1,572,940 $21.4 Million
Q1 2020

May 14, 2020

SELL
$4.1 - $10.24 $989,850 - $2.47 Million
-241,427 Reduced 13.98%
1,485,856 $11.3 Million
Q4 2019

Feb 14, 2020

BUY
$3.16 - $6.73 $43,535 - $92,719
13,777 Added 0.8%
1,727,283 $10.9 Million
Q3 2019

Nov 14, 2019

BUY
$3.55 - $5.4 $299,896 - $456,181
84,478 Added 5.19%
1,713,506 $6.72 Million
Q2 2019

Aug 15, 2019

BUY
$4.1 - $8.05 $6.68 Million - $13.1 Million
1,629,028 New
1,629,028 $7.89 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $386M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.